Members of the US FDA's Oncologic Drugs Advisory Committee may have problems using disease-free survival as a clinical trial endpoint, but they are not ready to dump it in favor of something else either.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?